10 ML ocrelizumab 30 MG/ML Injection [Ocrevus] — RxCUI 1876385
RxNorm drug concept · Semantic branded drug
RxCUI 1876385
Semantic branded drug · SBD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1876385
Official name10 ML ocrelizumab 30 MG/ML Injection [Ocrevus]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as10 ML Ocrevus 30 MG/ML Injection; Ocrevus 300 MG in 10 ML Injection; Ocrevus 300 MG per 10 ML Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)13,323 prescriptions · 48 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Ocrelizumab Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- No, it actually covers several types of MS. For adults, Ocrevus is approved for relapsing forms of MS — which includes clinically isolated syndrome, relapsing-remitting MS, and act...
- What exactly is Ocrevus used for — is it only for one type of MS?
- Ocrevus is given through an IV drip at a clinic or infusion center, not at home. Before the infusion starts, you'll be given a steroid, an antihistamine, and possibly a fever-reduc...
- What happens during an infusion — what should I expect?
🕸️ Concept Web — How 10 ML ocrelizumab 30 MG/ML Injection [Ocrevus] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
10 ML ocrelizumab 30 MG/ML Injection [Ocrevus]
RxCUI 1876385 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Ocrelizumab
1876366IN
-
Ocrelizumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Ocrevus
1876381BN
-
Ocrevus
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Ocrelizumab Injection
1876379SCDF -
Ocrelizumab Injectable Product
1876378SCDG -
Ocrelizumab Injection [Ocrevus]
1876383SBDF -
Ocrevus Injectable Product
1876384SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Ocrelizumab Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
10 ML ocrelizumab 30 MG/ML Injection
1876380SCD -
Ocrelizumab 30 MG/ML
1876377SCDC -
Ocrelizumab 30 MG/ML [Ocrevus]
1876382SBDC
-
10 ML ocrelizumab 30 MG/ML Injection
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
10 ML ocrelizumab 30 MG/ML Injection
SCD · 1876380 -
Ocrelizumab 30 MG/ML
SCDC · 1876377 -
Ocrelizumab Injection
SCDF · 1876379 -
Ocrelizumab Injectable Product
SCDG · 1876378
Brand-Name Concepts
-
Ocrelizumab 30 MG/ML [Ocrevus]
SBDC · 1876382 -
Ocrelizumab Injection [Ocrevus]
SBDF · 1876383 -
Ocrevus Injectable Product
SBDG · 1876384 -
Ocrevus
BN · 1876381
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 1876385 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 50242-0150-01 | 1 VIAL, SINGLE-USE in 1 CARTON (50242-150-01) / 10 mL in 1... | OCREVUS | Genentech, Inc. | 2017-03-28 |
Observed labelers:
Genentech, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | 1 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.